GMP warning letters issued by FDA in FY 1996 drop by 40% compared to previous year.
GMP WARNING LETTERS SENT BY FDA DROP BY 40% IN FY 1996 compared to the number of letters issued during the agency's fiscal year 1995. Between October 1995 and September 1996, FDA issued 59 GMP warning letters to drug manufacturers, repackers and testing laboratories, compared with a total of over 100 in each of the previous two fiscal years (110 in 1995 and 100 in 1994).
More from Archive
More from Pink Sheet
The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.
The reductions across medical product programs in the agency’s budget request include hundreds of positions funded by user fees, which may foreshadow its upcoming user fee restructuring strategy.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.